MedShr: the App for Doctors over One Million Members and fully live in the US



MedShr: the App for Doctors over One Million Members and fully live in the US

MedShr has grown to over one million members in 190 countries across all clinical specialties and is now fully live in the US.

Developed by doctors and launched from London (UK) in 2015, MedShr is a HIPAA, GMC and GDPR compliant app designed to empower medical professionals to safely discuss clinical cases using their own smartphone.

Now with over one million members worldwide, MedShr provides a unique digital channel for medical professionals to share their knowledge and skills, discuss complex and challenging cases, and learn from one another. Screening and diagnosis of coronavirus is currently among the trending topics, discussed at a global level between specialists and generalists alike with a unique perspective from a global health point of view.

Founder Dr. Asif Qasim said:

"MedShr is growing rapidly and has become a part of everyday clinical practice for many doctors through international specialty networks as well as local multi-disciplinary groups. I am incredibly proud of our members and the MedShr team for the work they have done to improve healthcare for patients around the world. We are looking forward to MedShr's continued growth in the US and Europe, and will be providing members with new features and services during 2020."

MedShr has won multiple awards including Facebook's Social Good App of the Year 2016, United Nations World Summit Award 2017 and ES SME Award in 2018, was a 2019 TechCrunch DT50 Award for Social Impact finalist, and was recently MedShr was named one of the UK's top 70 high growth technology companies. MedShr has also been shortlisted for the London Business Awards 2020.

The platform works in partnership with healthcare providers and hundreds of national and specialist medical societies, as well as the NHS, Health Education England and several Royal Colleges.

MedShr is now the world's leading case discussion app and is now fully live in the USA and building partnerships with US national and specialist medical societies.